Company TOT BIOPHARM International Company Limited

Equities

1875

HK0000545266

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

TOT BIOPHARM INTERNATIONAL COMPANY LIMITED

Delayed Hong Kong S.E. Other stock markets 11:49:16 29/04/2024 am IST			5-day change	1st Jan Change
1.74 ^HKD	+3.57%		+12.99%	-11.68%

15/03	TOT BIOPHARM International Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	TOT Biopharm's Loss Narrows in January-September Period	MT

TOT BIOPHARM International Company Limited is a company mainly engaged in the development and commercialization of oncology drugs and therapies. The Company has a portfolio of oncology drug candidates, which include monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), oncolytic virus products and specialty oncology drugs such as liposome drugs.

Number of employees: 552

HKD in Million	2021	Weight	2022	Weight	Delta
Anti-tumor Drugs and Self-developed Biological Drugs 100.0 %	92	100.0 %	514	100.0 %	+458.99%

HKD in Million	2021	Weight	2022	Weight	Delta
China 100.0 %	85	92.3 %	514	100.0 %	+505.67%

Managers	Title	Age	Since
Jun Liu CEO	Chief Executive Officer	56	17/16/17
Ben Xiao DFI	Director of Finance/CFO	42	01/22/01
Ming Liu CTO	Chief Tech/Sci/R&D Officer	63	28/17/28
Chun-Ying Yeh-Huang BRD	Director/Board Member	65	05/10/05
Shan Feng LAW	General Counsel	45	01/14/01
Yi Fan Chen SEC	Corporate Secretary	44	01/20/01
Wing Yat Lui SEC	Corporate Secretary	35	16/19/16
Chi-Yuen Wu PRN	Corporate Officer/Principal	52	01/16/01
Chun-Ming Lin SAM	Sales & Marketing	50	01/16/01
Xiaobao Chen PRN	Corporate Officer/Principal	42	20/16/20

Members of the board	Title	Age	Since
Chun-Ying Yeh-Huang BRD	Director/Board Member	65	05/10/05
Hong Jen Chang BRD	Director/Board Member	68	12/19/12
Shan Fu CHM	Chairman	56	19/16/19
Jun Liu CEO	Chief Executive Officer	56	17/16/17
Lan Hu BRD	Director/Board Member	53	12/19/12
Wei Dong Liu BRD	Director/Board Member	56	12/23/12
De Qian Wang BRD	Director/Board Member	73	12/22/12

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	772,787,887	448,300,187 ( 58.01 %)	0	58.01 %

Name	Equities	%	Valuation
Vivo Capital LLC 28.40 %	219,495,000	28.40 %	46 M $
CENTER LABORATORIES, INC. 27.60 %	213,311,700	27.60 %	45 M $
Chun-Ying Yeh-Huang 1.082 %	8,363,083	1.082 %	2 M $
Jun Liu 0.7376 %	5,699,999	0.7376 %	1 M $
Chengwei Capital Co. Ltd. 0.000000 %	0	0.000000 %	- $

TOT BIOPHARM International Co. Ltd.

No.120 Changyang Street Suzhou Industrial Park

, Suzhou

http://www.totbiopharm.com

address TOT BIOPHARM International Company Limited(1875)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.555 CNY

Average target price

3.486 CNY

Spread / Average Target

+124.16%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
TOT BIOPHARM INTERNATIONAL COMPANY LIMITED	-11.68%	166M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+0.96%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs